FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All Resources2024 US Conference – Sponsorship and Exhibitor Overview
Topic: Conference
Presentation
Free
Envisioning the Future of Clinical Supply Chains in the Next 10 Years
Topic: Supply Chain
Executive Summary
Members
GCSG Presentation Tips from Steve Jacobs
Topics: Communication, Personal Development
Conference Training
Members
